The prognostic value of mid-regional pro-adrenomedullin in the evaluation of acute dyspnea. Review uri icon

Overview

abstract

  • INTRODUCTION: Acute dyspnea is a common chief complaint among patients who visit an emergency room and presents diagnostic challenges for clinicians in both identifying the etiology and determining the clinical severity. The study of biomarkers in the prognostication and risk stratification of these patients has been increasing, including the investigation of the prognostic value for mid-regional pro-adrenomedullin (MR-proADM). Areas covered: In this review, the authors cover what is known about MR-proADM testing in patients presenting with acute dyspnea and the supporting evidence of its prognostic value in common conditions in medical patients with acute dyspnea, including acute heart failure, community acquired pneumonia, acute exacerbation of chronic obstructive pulmonary disease, and acute pulmonary embolism. Expert commentary: Numerous studies have proposed MR-proADM as a more accurate, prognostic tool in the evaluation of acute dyspnea than other biomarkers and consensus risk scores such as Sequential Organ Failure Assessment (SOFA) and quick SOFA (qSOFA). The authors review recent prospective studies, systematic reviews, and meta-analyses that demonstrate its prognostic value and role in risk stratification, including its use in biomarker-based triage algorithms as part of the diagnostic evaluation of the acutely dyspneic patient.

publication date

  • January 19, 2018

Research

keywords

  • Adrenomedullin
  • Biomarkers
  • Dyspnea

Identity

Scopus Document Identifier

  • 85041348389

Digital Object Identifier (DOI)

  • 10.1080/14737159.2018.1427069

PubMed ID

  • 29319365

Additional Document Info

volume

  • 18

issue

  • 2